These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions. Okada S; Konishi M; Ishii H BMJ Case Rep; 2016 Feb; 2016():. PubMed ID: 26917795 [TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome. Edgeworth A; Treacy MP; Hurst TP AIDS Rev; 2013; 15(3):171-80. PubMed ID: 24002201 [TBL] [Abstract][Full Text] [Related]
8. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522 [TBL] [Abstract][Full Text] [Related]
10. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. Mulligan K; Khatami H; Schwarz JM; Sakkas GK; DePaoli AM; Tai VW; Wen MJ; Lee GA; Grunfeld C; Schambelan M J Clin Endocrinol Metab; 2009 Apr; 94(4):1137-44. PubMed ID: 19174500 [TBL] [Abstract][Full Text] [Related]
11. Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome. Sekhar RV; Jahoor F; Iyer D; Guthikonda A; Paranilam J; Elhaj F; Coraza I; Balasubramanyam A Metabolism; 2012 Oct; 61(10):1395-403. PubMed ID: 22542724 [TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Hadigan C; Yawetz S; Thomas A; Havers F; Sax PE; Grinspoon S Ann Intern Med; 2004 May; 140(10):786-94. PubMed ID: 15148065 [TBL] [Abstract][Full Text] [Related]
13. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART). Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744 [TBL] [Abstract][Full Text] [Related]
14. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Brennan AM; Lee JH; Tsiodras S; Chan JL; Doweiko J; Chimienti SN; Wadhwa SG; Karchmer AW; Mantzoros CS Eur J Endocrinol; 2009 Feb; 160(2):173-6. PubMed ID: 19029226 [TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Miyazaki Y; DeFronzo RA Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983 [TBL] [Abstract][Full Text] [Related]
16. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. Addy CL; Gavrila A; Tsiodras S; Brodovicz K; Karchmer AW; Mantzoros CS J Clin Endocrinol Metab; 2003 Feb; 88(2):627-36. PubMed ID: 12574192 [TBL] [Abstract][Full Text] [Related]
17. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Carr A; Workman C; Carey D; Rogers G; Martin A; Baker D; Wand H; Law M; Samaras K; Emery S; Cooper DA; Lancet; 2004 Feb; 363(9407):429-38. PubMed ID: 14962523 [TBL] [Abstract][Full Text] [Related]